Showing results (231-240 of 254) with videos related to
Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.Internal Medicine Journal|October 19, 2021
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma AustraliaKatherine Creeper, Bradley Augustson, Kieran Kusel, et al.Nature Cancer|March 18, 2025
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trialWon Seog Kim, Tae Min Kim, Seok-Goo Cho, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaFrancine M Foss, Youn H Kim, H Miles Prince, et al.Blood|August 16, 2011
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphomaWerner Kempf, Katrin Pfaltz, Maarten H Vermeer, et al.Blood|December 29, 2025
Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaJeremy S Abramson, David J Straus, Nancy L Bartlett, et al.Blood|December 5, 2025
Early time to relapse as a survival prognosticator in mature T-cell/NK-cell lymphomas: results from the PETAL ConsortiumMark N Sorial, Luis Malpica, Carlos Sergio Chiattone, et al.British Journal of Haematology|April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataSusan E Bates, Robin Eisch, Alexander Ling, et al.Blood Advances|September 10, 2021
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final dataSteven M Horwitz, Julia J Scarisbrick, Reinhard Dummer, et al.Leukemia & Lymphoma|August 20, 2025
Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapyElżbieta Iskierka-Jażdżewska, Won Seog Kim, Seok-Goo Cho, et al.Pageof 26